UTSW-led study shows promise for upper urinary tract cancer drug

Chemotherapy disrupts gut microbiome in patients with breast cancer

Chemotherapy is known to cause behavioral side effects, including cognitive decline. Notably, the gut microbiome communicates with the brain to affect behavior, including cognition.

July 12, 2024

Vol.50 No.28

Clinical Roundup

Cells in tumor microenvironment play critical role in effectiveness of rapalogs

For nearly two decades, how kidney cancer becomes resistant to rapalog drugs has baffled the scientific community. Now, a study by researchers at UT Southwestern Medical Center’s Kidney Cancer Program sheds light.

June 14, 2024

Vol.50 No.24

Clinical Roundup

Combination therapy improves PFS, OS for metastatic colorectal cancer in phase Ib/II study

A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone. The work will be presented at the 2024 ASCO Annual Meeting.

May 31, 2024

Vol.50 No.22

Clinical Roundup

UCLA study: Combination of breast cancer and chemo may speed physical decline in older adults

Women who are 65 years old or older with high-risk breast cancer and are treated with chemotherapy are more likely to develop a substantial decline in physical function, a UCLA-led study suggests.

May 17, 2024

Vol.50 No.20

Drugs & Targets

FDA, EMA grant Orphan Drug Designation to Carthera for carboplatin with SonoCloud technology in glioma

FDA and the European Medicines Agency granted an Orphan Drug Designation to Carthera for the use of carboplatin when used with SonoCloud technology in the treatment with malignant glioma.

May 17, 2024

Vol.50 No.20

Clinical Roundup

PRMT5 inhibitor combination overcomes drug resistance in ER+ breast cancer

Shutting down a gene called PRMT5 stopped metastatic estrogen receptor-positive breast cancer cells from growing after they acquired resistance to a standard therapy known as CDK4/6 inhibitors, UT Southwestern Medical Center researchers showed in a new study.

April 26, 2024

Vol.50 No.17

UTSW-led study shows promise for upper urinary tract cancer drug

YOU MAY BE INTERESTED IN

Chemotherapy disrupts gut microbiome in patients with breast cancer

Cells in tumor microenvironment play critical role in effectiveness of rapalogs

Combination therapy improves PFS, OS for metastatic colorectal cancer in phase Ib/II study

UCLA study: Combination of breast cancer and chemo may speed physical decline in older adults

FDA, EMA grant Orphan Drug Designation to Carthera for carboplatin with SonoCloud technology in glioma

PRMT5 inhibitor combination overcomes drug resistance in ER+ breast cancer

Renew today!

Subscriber content

Login